Research Article
Incidence, Clinical Features, and Outcomes of the Confirmed Neonatal COVID-19 Infection in the Southwest Iran
Table 2
Clinical and paraclinical features of infants with confirmed COVID-19 infection.
| | Characteristics of the neonates | Infant outcome | | Total () | Recovered (20, 80%) | Deceased (5, 20%) |
| | Postnatal age at admission (days) | 4 (0-25) | 2 (0-25) | 12 (10-27) | | Duration between symptom onset to detection (days) | 2 (0-14) | 2 (0-14) | 2 (1-14) | | Hospitalization duration (days) | 10 (1-29) | 10.5 (1-29) | 9 (3-19) | | Neonatal clinical symptoms | | | | | Fever | | | | | Yes | 12 (48%) | 10 (83.4%) | 2 (16.6%) | | No | 13 (52%) | 10 (76.9%) | 3 (23.1%) | | Cough | | | | | Yes | 2 (8%) | 2 (100%) | 0 (0%) | | No | 23 (92%) | 18 (78.3%) | 5 (21.7%) | | Respiratory distress | | | | | Yes | 9 (64%) | 5 (55.6%) | 4 (44.4%) | | No | 16 (36%) | 15 (93.7%) | 1 (6.3%) | | Lethargy | | | | | Yes | 12 (48%) | 9 (75%) | 3 (25%) | | No | 13 (52%) | 11 (84.6%) | 2 (15.4%) | | Poor feeding | | | | | Yes | 13 (52%) | 10 (76.9%) | 3 (23.1%) | | No | 12 (48%) | 10 (83.3%) | 2 (16.7%) | | Gastroenteritis | | | | | Yes | 3 (12%) | 3 (100%) | 0 (0%) | | No | 22 (88%) | 17 (77.3%) | 5 (22.7%) | | Asymptomatic | | | | | Yes | 0 | 0 (0%) | 0 (0%) | | No | 25 (100%) | 20 (80%) | 5 (20%) | | Neonatal laboratory tests | | | | | C-reactive protein | | | | | Positive | 2 (8%) | 1 (50%) | 1 (50%) | | Negative | 20 (80%) | 18 (90%) | 2 (10%) | | White blood cell count (cells/L) | | | | | <4000 | 2 (8%) | 1 (50%) | 1 (50%) | | 4000-12000 | 13 (52%) | 11 (84.6%) | 2 (15.4%) | | >12000 | 7 (28%) | 7 (100%) | 0 (0%) | | Lymphocyte (%) | | | | | <20% | 1 (4%) | 0 (0%) | 1 (100%) | | 20-40% | 5 (20%) | 5 (100%) | 0 (0%) | | >40% | 6 (24%) | 6 (100%) | 0 (0%) | | Neutrophil (%) | | | | | <20% | 2 (8%) | 2 (100%) | 0 (0%) | | 20-40% | 3 (12%) | 3 (100%) | 0 (0%) | | >40% | 7 (28%) | 6 (85.7%) | 1 (14.3%) | | Platelets | | | | | <150 | 3 (12%) | 2 (66.7%) | 1 (33.3%) | | 150-450 | 16 (64%) | 15 (93.7%) | 1 (6.3%) | | >450 | 3 (12%) | 2 (66.7%) | 1 (33.3%) | | Close contact COVID-19 | | | | | Yes | 13 (52%) | 12 (92.3%) | 1 (7.7%) | | No | 9 (36%) | 5 (55.6%) | 4 (44.4%) | | Family history of COVID-19 | | | | | Yes | 9 (369%) | 8 (88.9%) | 1 (11.1%) | | No | 12 (48%) | 9 (75%) | 3 (25%) | | NICU admission | | | | | Yes | 18 (72%) | 13 (72.2%) | 5 (27.8%) | | No | 7 (28%) | 7 (100%) | 0 (0%) | | Mechanical ventilation | | | | | Yes | 6 (24%) | 3 (50%) | 3 (50%) | | No | 19 (76%) | 17 (89.4%) | 2 (10.6%) | | Antibiotic therapy | | | | | Yes | 25 (100%) | 20 (80%) | 5 (20%) | | No | 0 (0%) | 0 (0%) | 0 (0%) | | Corticosteroids | | | | | Yes | 6 (24%) | 4 (66.7%) | 2 (33.3%) | | No | 19 (76%) | 16 (84.2%) | 3 (15.8%) | | Antiviral medication | | | | | Yes | 1 (4%) | 0 (0%) | 1 (100%) | | No | 24 (96%) | 0 (0%) | 0 (0%) |
|
|
